Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human Models of Selective Insulin Resistance: Pancreatic Clamp
NCT06558422Phase 1Not yet recruiting
- Sponsor
- Columbia University
- Start
- Jan 2027
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of regular human insulin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Columbia University. Primary endpoints: Hepatic de novo lipogenesis (absolute value) up to 6.5 hours, Hepatic de novo lipogenesis (relative value) up to 6.5 hours and 4 more. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
regular human insulin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06558422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06558422.